Strontium enhances osseointegration of calcium phosphate cement: a histomorphometric pilot study in ovariectomized rats by Martin Baier et al.
Baier et al. Journal of Orthopaedic Surgery and Research 2013, 8:16
http://www.josr-online.com/content/8/1/16RESEARCH ARTICLE Open AccessStrontium enhances osseointegration of calcium
phosphate cement: a histomorphometric pilot
study in ovariectomized rats
Martin Baier1, Patric Staudt2, Roman Klein2, Ulrike Sommer2, Robert Wenz3, Ingo Grafe2, Peter Jürgen Meeder1,
Peter P Nawroth2 and Christian Kasperk2*Abstract
Background: Calcium phosphate cements are used frequently in orthopedic and dental surgeries. Strontium-containing
drugs serve as systemic osteoblast-activating medication in various clinical settings promoting mechanical stability of the
osteoporotic bone.
Methods: Strontium-containing calcium phosphate cement (SPC) and calcium phosphate cement (CPC) were
compared regarding their local and systemic effects on bone tissue in a standard animal model for osteoporotic
bone. A bone defect was created in the distal femoral metaphysis of 60 ovariectomized Sprague-Dawley rats. CPC
and SPC were used to fill the defects in 30 rats in each group. Local effects were assessed by histomorphometry at
the implant site. Systemic effects were assessed by bone mineral density (BMD) measurements at the contralateral
femur and the spine.
Results: Faster osseointegration and more new bone formation were found for SPC as compared to CPC implant
sites. SPC implants exhibited more cracks than CPC implants, allowing more bone formation within the implant.
Contralateral femur BMD and spine BMD did not differ significantly between the groups.
Conclusions: The addition of strontium to calcium phosphate stimulates bone formation in and around the
implant. Systemic release of strontium from the SPC implants did not lead to sufficiently high serum strontium
levels to induce significant systemic effects on bone mass in this rat model.
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Implant materials on the basis of calcium phosphate are
frequently used with the goal of complete osseointegration
and eventual substitution by the bone tissue [1-3]. Factors
modulating bone formation are added to some implant
materials to enhance osseointegration. The release of
these factors occurs either spontaneously or as a con-
sequence of the bony replacement of the implant. There
have been numerous reports on osseous integration of
organic and inorganic implant materials releasing growth
factors like bone morphogenetic protein 2 (BMP-2) [4-7],* Correspondence: christian.kasperk@med.uni-heidelberg.de
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reproduction in any medium, provided the orbone morphogenetic protein 7 (BMP-7) [8], fibroblast
growth factor 2 (FGF-2) [9], platelet-derived growth factor
[10], and insulin-like growth factors [11]. Some of these
products are available for routine procedures. Although
most of the published preclinical reports demonstrate a
faster healing of osseous defects within the first 2 to 3
weeks, the clinical long-term relevance of these observa-
tions in animal experiments remains unclear.
Strontium administered systemically increases bone
mass by stimulating osteoblastic activity [12-14] and
simultaneously inhibiting bone resorption [15-17]. In
preclinical experiments, oral administration of strontium
ranelate prevented ovariectomy-induced bone loss in
rats [15]. Subsequent clinical trials demonstrated a
significant fracture prevention after strontium ranelated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Calcium phosphate implant in rat femur after
implantation. Section of a representative specimen of the distal
right femur with cement implant (CPC, 3 months post implantation).
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SOTI [19] studies).
We hypothesized that adding of strontium to calcium
phosphate cement implants may improve osseous inte-
gration of the implant into the osseous implant bed and
may also increase bone formation locally at the im-
planted skeletal site and systemically at the contralateral
skeletal site and at the spine.
Osseointegration-stimulating properties of a bone
substitute are of particular interest in an osteoporotic
skeleton, which does not provide an optimal bone struc-
ture for surgical implantation procedures. To address
this problem, we chose the ovariectomized rat model
[20,21] which is the standard animal model for the
histomorphometric evaluation of bone healing in the
osteoporotic bone.
The goals of our study were to assess osseointegration,
compare calcium phosphate cement implants containing
strontium (SPC) to calcium phosphate cement implants
(CPC), and to determine whether a locally applied
strontium-containing implant has systemic effects on
bone mass.Materials and methods
Animal experiments
The animal experiment was conducted in accordance with
the guidelines set forth by the local animal protection com-
mittee of the regional government (Regierungspräsidium
Karlsruhe, file number AZ 35-9185.82/A-49/04).
A standard animal model [20] for osteoporosis was
used: 60 female Sprague-Dawley rats were ovariecto-
mized at the age of 10 weeks under anesthesia with
intraperitoneal injection of 100 mg/kg ketamine and
3 mg/kg xylazine and subcutaneous injection of car-
profen (all three chemicals supplied by Pfizer, 76139
Karlsruhe, Germany).
Two months after ovariectomy, osteopenia was assessed
by dual energy X-ray absorptiometry (Piximus device by
GE, Fairfield, CT, USA). Successful ovariectomy-induced
loss of bone mass was verified by measuring bone mineral
density at the left femur (distal metaphysis) which
exhibited a decrease of bone mineral density by 12% after
3 months as evaluated by the comparison to intact con-
trols (data not shown).
Surgical procedure. In anesthesia, the right distal femur
was exposed through a lateral approach. With a 2-mm
drill, a bone defect was created proximal to the distal fe-
moral growth line in the lateral femoral cortex and the
metaphyseal cancellous bone. The left femur was not op-
erated on and served as control.
In 30 animals, the defect was filled with 0.25 ml of
CPC and in another 30 animals with the same volume of
SPC (Figure 1).Cement
Calcium phosphate cement
The solid phase of CPC consisted of 61% tricalcium phos-
phate (TCP), 26% calcium hydrogen phosphate (CaHPO4,
anhydrous), 10% calcium carbonate (CaCO3), and 3% pre-
cipitated hydroxyapatite (pHA). The liquid phase of CPC
was an aqueous solution of 2% disodium hydrogen phos-
phate (Na2HPO4). The compression strength of CPC was
60 MPa (24 h after preparation).
Strontium-containing calcium phosphate cement
The solid phase of SPC consisted of 65.2% tricalcium
phosphate (TCP), 21.8% strontium hydrogen phosphate
(SrHPO4, anhydrous), 10.8% strontium carbonate (SPCO3),
and 2.2% precipitated hydroxyapatite (pHA). The liquid
phase of SPC was an aqueous solution of 3 M dipotassium
hydrogen phosphate (K2HPO4) and 1.5 M potassium
dihydrogen phosphate (KH2PO4), with a volume ratio of
1:1. The compression strength of SPC was 34 MPa (24 h
after preparation).
Histomorphometric evaluation
After embedding the specimen in polymethylmethacrylate
(PMMA), the slices for histological evaluation were gained
by slicing the PMMA blocks containing undecalcified
bone specimen with a diamond band saw (Exakt GmbH,
Norderstedt, Germany) and subsequent grinding of the
slices to a thickness of 100 μm. The thin ground sections
were mounted on plastic slides and photographed digitally
with 25-fold magnification. Measurements were performed
with AxioVision software (Carl Zeiss Vision GmbH,
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parameters were determined:Circumferential contact index
Implant circumference (c in Figure 2) and the length of all
circumferential segments with direct contact between im-
plant and bone (b in Figure 2) were measured. Circum-
ferential contact index was defined as (b / c × 100 (%)).
This parameter was determined at 1, 3, and 6 months after
implantation. Contact segments of newly formed bone
within the implant were ignored in order to keep this par-
ameter independent from the other parameters mentioned
below (Figure 2).Figure 3 Ingrowth index. The relative area of newly formed bone
within the implant was measured (SPC, 6 months after
implantation). Ingrowth index was defined as (I / A × 100 (%)).Ingrowth index
Cement implant area (A in Figure 3) and the area of newly
formed bone within the implant (I in Figure 3) were mea-
sured. Ingrowth index was defined as (I / A × 100 (%)).
This parameter was determined at 1, 3, and 6 months after
implantation (Figure 3).Implant discontinuities
The total number of discontinuities within the implant and
the number of discontinuities containing newly formed
bone were counted at 1, 3, and 6 months after implant-
ation. Only discontinuities with a length greater than half
of the implant diameter were considered (Figure 4).Figure 2 Circumferential contact index. Example of SPC,
6 months after implantation): On the outer surface of the implant,
the length of all circumferential segments with direct contact
between cement and bone (b = sum of all red lines) as well as the
total implant circumference (c) were measured. Circumferential
contact index was defined as (b / c × 100 (%)).Evaluation of systemic effects
Bone mineral density measurement
In order to evaluate whether locally applied SPC or CPC
in the right femur differ in their potential systemic effects
on bone mineral density (BMD), BMD was measured with
dual X-ray absorptiometry (Piximus device by GE) in the
distal metaphysis of the left femur and in the cancellous
bone of the second coccygeal vertebra.Figure 4 Number of discontinuities. The total number of
discontinuities was counted: This specimen has two implant
discontinuities (red arrows) containing newly formed bone (SPC,
6 months after implantation).
Figure 5 Circumferential contact index. Circumferential contact
index for calcium phosphate cement (CPC) and strontium-containing
calcium phosphate cement (SPC) at 1, 3, and 6 months after
implantation. Three months after implantation, the circumferential
contact index is significantly higher for SPC as compared to CPC
(p = 0.009, as indicated by double asterisk) (mean values ± standard
error, using two-sided Mann-Whitney U test for comparison between
CPC and SPC at equal points in time with significance level at p < 0.05).
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Blood samples of all animals with SPC implants were
taken directly after killing. Serum levels of strontium
were measured by mass spectrometry.
Statistical analysis
The Mann-Whitney U test (two-sided, with significance
level of p < 0.05) was applied to compare CPC and SPC
groups at equal time points (1, 3, and 6 months after im-




One month after implantation, the circumferential con-
tact index did not differ significantly between the CPC
and SPC groups. At 3 and 6 months, circumferential
contact index was higher in the SPC group as compared
to the CPC group; however, after 6 months this differ-
ence was not significant anymore. In both groups, SPC
and CPC, the circumferential contact index increased
over time (Figure 5).
Ingrowth index
One month and three months after implantation, the in-
growth index did not differ significantly between the
CPC and SPC groups. At 6 months, both groups differed
in a highly significant way: While ingrowth index in the
CPC group was only 0.33%, it was 3.79% in the SPC
group (p = 0.0002) (Figure 6), indicating that after
6 months, a higher percentage of more than ten times
in intra-implant bone formation occurred within the
SPC implants.
Implant discontinuities
There were significantly more discontinuities in SPC im-
plants as compared to CPC implants. This was statistically
significant at 3 and 6 months after implantation (Figure 7).Table 1 Sample sizes for statistical analyses
Histological measurement BMD measurement
CPC (n) SPC (n) CPC (n) SPC (n)
1 month 8 9 10 9
3 months 8 10 9 10
6 months 9 7 9 9
Of the 60 animals distributed into six groups of ten animals each (CPC and SPC
at 1, 3, and 6 months), some got lost for BMD and/or histological
measurement. In the 1-month group, two CPC implants disintegrated during
preparation, and one animal with SPC had died earlier for unknown reasons. In
the 3-month group, one CPC implant disintegrated during preparation, and
one animal with CPC had died earlier for unknown reasons. In the 6-month
group, two SPC implants disintegrated during preparation, and one animal
with CPC and one with SPC had died earlier for unknown reasons.
Figure 6 Ingrowth index for CPC and SPC at 1, 3, and 6 months
after implantation. At 6 months, ingrowth index is significantly
higher for SPC as compared to CPC (p = 0.0002, as indicated by
triple asterisks) (mean values ± standard error, using two-sided
Mann-Whitney U test for comparison between CPC and SPC at
equal points in time with significance level at p < 0.05).
Figure 7 Implant discontinuities. Number of implant discontinuities
and number of implant discontinuities containing newly formed bone
at 1, 3, and 6 months post-implantation. Three months and six months
post-implantation, SPC has significantly more discontinuities than CPC.
Six months post-implantation, the number of discontinuities
containing the newly formed bone is significantly higher in SPC as
compared to CPC (mean values ± standard error, using two-sided
Mann-Whitney U test for comparison between CPC and SPC at equal
points in time with significance level at p < 0.05).
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bone within these discontinuities increased over time. This
effect was much more pronounced in SPC than in CPC im-
plants. Six months after implantation, SPC implants had a
significantly higher number of bone-containing discontinu-
ities (on average of 1.5 in SPC and 0.2 in CPC; p = 0.0079,
indicated by double asterisks) (Figure 7).Systemic parameters
Bone mineral density
BMD results are shown in Table 2. No significant differ-
ence was found between CPC and SPC groups. However,
in the SPC group, there was a consistent increase of
bone mineral density in the distal metaphyses of the left
(contralateral to the femoral implant site) femora during
the observation period.Table 2 Bone mineral density during 6 months
of observation
Coccygeal vertebrae Left femora
CPC SPC CPC SPC
1 month 0.261 ± 0.020 0.274 ± 0.025 0.257 ± 0.015 0.254 ± 0.038
3 months 0.261 ± 0.021 0.256 ± 0.031 0.262 ± 0.016 0.267 ± 0.018
6 months 0.264 ± 0.012 0.266 ± 0.026 0.256 ± 0.019 0.275 ± 0.026
Bone mineral density (g/cm2) of the second coccygeal vertebrae and at the
distal metaphyses of the left femora 1, 3, and 6 months after implantation
(arithmetic mean ± standard deviation).Serum strontium levels
Serum strontium concentrations (mean ± standard devi-
ation) in the SPC group at 1, 3, and 6 months were
10.87 ± 4.16 μg/l, 3.73 ± 0.88 μg/l, and 1.80 ± 0.39 μg/l,
respectively.
Discussion
Local effects of strontium-containing cement
This work demonstrates that the addition of strontium to
calcium phosphate cement enhances local bone formation
in ovariectomized rats, both on the implant surface and
within the implant. In vitro experiments provide possible
explanations for the observed bone formation stimulating
effect of locally applied strontium. Divalent strontium ions
enhance the replication of pre-osteoblastic cells and bone
matrix synthesis by binding to the calcium receptor and
stimulation of local growth factor and osteoprotegerin
production [13,22,23].
The histomorphometric evaluation of the implants sug-
gests that the degradation process of calcium phosphate
implants is based on the formation of discontinuities
within the implant, which are subsequently filled with
newly formed bone. While the number of discontinuities
in calcium phosphate implants remained constant over
the observation period, the number of discontinuities
gradually increased in strontium-containing implants.
Bone formation within implant discontinuities was
strongly influenced by the presence of strontium. More
than nine out of ten discontinuities in strontium cement
implants contained newly formed bone after 6 months,
compared to only four out of ten discontinuities in cal-
cium phosphate cement implants.
The physicochemical properties of the strontium-
containing implant determine its osteotropic effects
and its mechanical properties. The solubility of calcium
phosphates in which part of the Ca2+ ions are replaced by
Sr2+ ions increases with increasing content of strontium
ions due to the larger atomic radius of Sr2+ which reduces
crystallinity and alters the crystal lattice [24-27]. The
higher solubility of the SPC compared to the CPC could
also explain the higher degree of discontinuities within the
SPC group, which may compromise the biomechanical
stability of the implant.
Different types of strontium-containing cements have
been tested in vivo previously: In rabbit non-osteoporotic
cancellous bone, an injectable strontium-containing ce-
ment with an acrylate component was compared to
PMMA cement [28]. The stimulation of bone formation
at the bone-implant interface was found on strontium-
containing cement surfaces only, whereas inflammatory
responses, necrosis, and a fibrous layer were found at the
PMMA-cement-bone interface [28]. Another calcium
phosphate cement containing strontium and acrylate was
developed by Lu, Cheung, and co-workers, which also
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containing cement [29,30]. Guo Dagang and co-workers
[31,32] demonstrated biocompatibility and degradability
of their strontium-containing hydroxyapatite in rabbit
muscle and cancellous bone.
The addition of strontium to different types of cement
also affects the compression strength of the material in
different ways. Panzavolta et al. [23] describe a strontium-
enriched gelatin-calcium phosphate cement: Its compres-
sive strength decreases with increasing strontium content
(0.1% to 5%). However, Wang et al. [33], who added stron-
tium carbonate as a radio-opacifier to calcium phosphate
cement, observed an increase in compressive strength
from 0 wt.% to 8 wt.% strontium carbonate but with a
subsequent decrease in compressive strength when in-
creasing the strontium carbonate content to 20 wt.%. The
absolute figure for compression strength for cement with
20 wt.% strontium [31-33] was similar to the one in our
study (36 MPa as compared to SPC used in our study with
34 MPa). It is unclear how mechanical cement properties
affect the degradation processes in bone tissue. Cements
implanted into a cavity surrounded by femoral bone - as
performed in our study - are somewhat shielded from
mechanical loading. Despite this shielding, compressive
forces and shear stress within the implant are possibly due
to the elastic deformation of the surrounding bone when
the animal puts weight on the femur when moving. It is
therefore likely that formation of discontinuities and even-
tually cement degradation is influenced by the mechanical
properties of the cement, which may also have clinical im-
plications when calcium phosphate cements are implanted
in bone sites exposed to shear stress rather than compres-
sive force.
Unlike the local positive effects of strontium-containing
cements on osseointegration, we did not find a significant
systemic effect on bone density of strontium-containing
cement implants. BMD in the examined vertebrae did not
differ between animals with calcium phosphate and
strontium-containing calcium phosphate implants in the
right femur. In the contralateral femur, bone mineral
density increased by approximately 8% in animals with
strontium-containing cement from 1 to 6 months after
implantation. No such increase was observed in the cal-
cium phosphate group; however, the difference in BMD
values between the SPC and CPC groups was not signifi-
cant at any point in time. When considering these obser-
vations, we have to keep in mind a peculiarity of the used
rat animal model. The ovariectomized rats' skeleton is still
growing during the observation period, and the growth
rate at the epiphyseal plates is usually high in ovariecto-
mized rats [34]. If the serum levels of strontium are ele-
vated shortly after implantation, part of the serum
strontium is likely to be deposited in the growing bone.
The more bone tissue is growing, the more strontium canbe deposited into the newly formed bone matrix, and in
fact higher concentrations of strontium were observed in
newly formed bone than in old bone in other studies
[35,36]. BMD measurements in strontium-containing
bone are falsely high, due to the higher atomic number
(Z = 38) of strontium as compared to calcium (Z = 20)
[25,37,38]. The increase in femoral BMD over time while
vertebral BMD remains unchanged may therefore be due
to the differences in relative growth between the femur
and spine during the observation period.
Another possible reason for increased contralateral fe-
moral BMD while spinal BMD remains unaffected could
be the different loading conditions of the respective skel-
etal sites. In the rat, mechanical load on the coccygeal ver-
tebrae is lower compared to the load on a weight-bearing
femur. A study which investigated an effect of different
loading conditions on BMD under systemic application of
strontium was performed by Hott et al. [39]: Bone resorp-
tion induced by immobilization in rats can be suppressed
by systemic administration of strontium. Whether bone
formation under application of strontium is possibly en-
hanced by mechanical loading or not has not been shown.
Oral administration of strontium ranelate increases
bone mineral density in ovariectomized rats' femur, even
after correction for higher X-ray absorption [15]. The
lowest strontium ranelate dose in a rat experiment of
77 mg/kg/day orally led to a serum strontium concentra-
tion of 24.2 μg/l [15], which is more than twice the
concentration we measured in the serum 1 month after
implantation of the strontium-containing cement. The
oral dose that raised BMD most in the study by Marie
et al. [15] (308 mg/kg/day) led to a serum strontium
concentration of 127.6 μg/l, which is an order of magni-
tude higher than our highest serum concentration. In
another study, Marie et al. demonstrated a substantial
improvement of mechanical properties of the fifth
lumbar vertebra in ovariectomized rats treated with oral
strontium ranelate (625 mg/kg/day) [40]. Ultimate
strength was increased by 26% and energy to failure by
75%. To achieve this mechanical improvement, the max-
imum oral strontium dose of their previous study [15]
was more than doubled. The serum strontium con-
centration necessary to produce systemic effects was
approximately 100 times higher than the one measured
in our study [41].
There are several shortcomings of our study. The mech-
anical properties of the utilized cements in this study were
tested under in vitro conditions by the manufacturer.
Thus, it is unclear whether the indicated compressive
strengths of the two cement types in our study remain
constant after in vivo implantation. Confounding factors
are the presence of body fluids and possible mechanical
stress by inserting instruments during the crystallization
phase; the surgical application procedure may at least in
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play a role in the subsequent degradation processes,
thereby influencing resorption and eventually replacement
of the implant.
The cements used in our study are resorbable; how-
ever, due to the lack of a long-term follow-up, we do not
know whether the used cements are indeed replaceable
by bone tissue and to what extent.
The parameters ‘ingrowth index’ and ‘implant dis-
continuities containing bone’ are not independent of each
other and thus describe the osseointegration characteris-
tics of the used cements with different parameters. After 6
months, a large proportion of the bone tissue quantified
by the ingrowth index was actually located within linear
implant discontinuities. New bone formation on the cir-
cumference of the original implant (‘circumferential con-
tact index’), however, has been quantified as a parameter
which is independent from the ingrowth indices (ingrowth
index and implant discontinuities containing bone).
When assessing the bone mineral density after applica-
tion of the implant containing strontium, we did not
correct the higher X-ray absorption of strontium. Our
BMD measurement may therefore produce falsely high
values. This must be taken into account in case our
absolute values are to be compared with others. The in-
terpretation of our results, however, remains unchanged
even if we corrected for bone strontium content, as we
did not detect any significant systemic effects of locally
applied strontium-containing implants on BMD at other
skeletal sites.
Conclusions
The addition of strontium to calcium-phosphate cement
leads to a faster osseointegration of the implant into the
osteoporotic bone. Strontium-containing implants stimu-
late, at least initially, local bone formation and are partly
replaced by bone within 6 months.
Serum concentrations of strontium caused by release
from the strontium-containing implants in this model
are too low to stimulate systemic bone formation and
thus do not increase bone mineral density systemically.
The clinical relevance of the observation of an initially
faster osseointegration of strontium-containing implants
and its biomechanical implications still have to be demon-
strated by a long-term, randomized, controlled clinical trial.
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